All In Biotech

Drug Trial Radar · NCT05339321

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

A Phase 1 Clinical Study of Autologous HBV-specific TCR-T Cell Therapy (SCG101) in Patients With HBV-related HCC

Last checked: Nov 19, 2026Latest source record: May 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

36

Planned (sponsor's estimate)

Start

Apr 14, 2021

Primary completion

Jul 2023

Study completion Dec 2023

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Adoptive cell therapy with TCR-T cells targeting HBV antigens represents an innovative opportunity for treatment of HBV-related HCC. SCG101 is a genetically modified autologous TCR-T cell therapy with a natural high-avidity TCR directed towards the HLA-A\*02-restricted HBsAg peptide. This is a phase 1 clinical study of SCG101 alone and with PD-1/PD-L1 checkpoint inhibitors in HBV-related HCC.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • SCG101Genetic

    SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.

  • PD1/PD-L1 checkpoint inhibitorBiological

    Commercially approved for HCC treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT)Time frame: 28 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, China · Recruiting

  • The Sixth People's Hospital of Shenyang

    Shenyang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.